Venetoclax

Chemical formula: C₄₅H₅₀ClN₇O₇S Molecular mass: 868.45 g/mol PubChem compound: 49846579

Therapeutic indications

Venetoclax is indicated for:

Chronic lymphocytic leukaemia (CLL)

Population group: only adults (18 years old or older)

Venetoclax in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).

Venetoclax in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.

Venetoclax monotherapy is indicated for the treatment of CLL:

in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor, or
in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

20-400 mg once daily

Contraindications

Venetoclax is contraindicated in the following cases:

Strong CYP3A inhibitors

at least one of

Strong CYP3A4 inhibitors
Cytochrome P-450 CYP3A5 strong inhibitors

St. John's wort

Hypericum perforatum (St John's Wort)

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.